Table 2.
Genomic distribution of MLV vector integration sites in PBL-GT and HSC-GT
| Patient samples | Inside gene (%) | Outside gene (%) | 10 kb window on TSS (%) | Clustered in CIS (%) |
|---|---|---|---|---|
| PBL-GT pre-GT CD3+ | 55.9 | 44.1 | 27.6 | 43.4 |
| PBL-GT post-GT CD3+ | 51.3 | 48.7 | 23.6 | 34.0 |
| PBL-GT total | 54.1 | 45.9 | 26.1 | 39.8 |
| HSC-GT pre-GT CD34+ | 52.6 | 47.4 | 20.0 | 36.1 |
| HSC-GT post-GT CD3+ | 40.7 | 59.3 | 23.0 | 44.8 |
| HSC-GT post-GT CD15+ | 40.6 | 59.4 | 23.8 | 15.8 |
| HSC-GT total | 46.1 | 53.9 | 21.8 | 39.4 |
| Randomly generated RIS | 40.7 | 59.3 | 2.1 | NA |
| Human genome | 35.5 | 64.5 | ND | NA |
Percentages of integrations in vitro and in vivo from PBL-GT (blue) and HSC-GT (red) landing inside genes, outside genes, in a 10 kb window centred on TSS of genes and involved in CIS in vitro and in vivo in PBL-GT or HSC-GT. Percentages relative to 100.000 random insertions and human genome reference are also shown for comparison (ND, not done; NA, not available).